Modulation of Plasma 25-Hydroxyvitamin D3 Level by Imatinib Mesylate in Patients with Chronic Myelogenous Leukemia: The Role of Uptake and Efflux Transporters

• Main Authors: Mervat M. Omran, MD (Author), Samia A. Shouman, PhD (Author), Raafat Abdelfattah, MD (Author), Heba S. Moussa, MD (Author), Nadia A. Thabet, Msc (Author), Marwa S. Hamza, PhD (Author)
• Formato: Livro
• Publicado em: Elsevier, 2022-01-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

ABSTRACT: Background: Vitamin D deficiency is a common side effect of imatinib mesylate (IM) therapy. Transporter polypeptides involved in the disposition of IM may be required for maintenance of adequate vitamin D concentrations. Objective: The aim of the present work is to study the association be...